Does anyone have a link that provides a comprehnesive listing of which places are doing what vaccine trials? Doing a search I just come up with individual hospitals/schools. I was reading through a few last night.I see the CMV vaccine is really being stressed.CMV is dangerous for a fetus just like rubella.And like rubella the illness isn't usually a big issue with children and adults,but it will probably become a routine schedule vaccine soon.Herpes 2 vaccine trials going on with women as the major focus.Doesn't say if it is a live one,but I am assuming if you get 4 doeses it is probably inactiviated.I read that so far it looks 70% effective. RSV and flu vaccines trials on kids.
I noticed this one(posted below) about trying to figure out which type of DTaP causes the most reactions as a fifth dose in those kids who had serious reactions with the 4th dose.Really made me mad when I read the part where it says your child needs to have a 5th dose of DTaP to get into school.These kids should NOT be getting any more doses preiod.Oh and that reminds me of the study in teens/adults using a TdcP vaccine(teens and adults spread pertussis so a safe pertussis vaccine is needed for them).
<<
Safety of a Fifth Dose of Diphtheria Tetanus Acellular Pertussis Vaccine (DTaP) in Children Who Had an Extensive Local Reaction After the Fourth DTaP Dose. (Revaccination Study)
SUMMARY: Diphtheria, tetanus, and pertussis are infections that still exist in the world and may cause outbreaks of disease if children are not vaccinated. A vaccine, DTaP, is a childhood immunization, given in a series of 5 injections, that protects children against all three of these infections. Approximately 2% of children have a large area of swelling at the vaccination site after the 4th and/or 5th dose of DTaP. There may also be redness and pain. The reactions go away in a few days. It is not known if a child who had a reaction after dose 4 is more likely to again react to the 5th dose. It is also not known if reactions are more common with some DTaP vaccines than other vaccines. Different DTaP vaccines contain different amounts of vaccine parts. There are currently three DTaP vaccines approved by the FDA for us in the U.S. There are three main purposes of this study: 1) to determine rates and severity of swelling after a 5th dose of DTaP in children who were reported by their parents or health care providers to have had a bad local reaction after dose 4; 2) to compare rates of swelling among two different DTaP vaccines; and 3) to compare antibody levels (proteins that fight germs) in the blood of children who had reactions to those who did not have swelling reactions.
Subjects will have two study visits, the first for a blood sample and to receive their 5th dose of DTaP which is required for entry into school.
The second visit will be solely for a blood sample. This information will help doctors find out why children have these reactions, and also, if one vaccine is more likely to cause this severe swelling reaction. Subjects will receive reimbursement for their participation.
ELIGIBILITY: Children of either sex and any race between the ages of 4 to 6 years will be eligible to enroll as cases if the parent or their medical practitioner were concerned that they had experienced an extensive local reaction after the 4th dose of a DTaP vaccine, and if they have not yet received their 5th DTaP booster dose.
SUMMARY-Human Cytomegalovirus (HCMV) is a common virus that infects most people at some time in their lives. It is not a well-known virus because it does not cause symptoms in most people. The purpose of this study is to understand better how this virus behaves when it infects healthy infants and how the body’s immune system controls the infection. Improved knowledge about HCMV infection in healthy infants is needed because HCMV can cause serious damage to an infant before birth if the mother becomes infected during pregnancy. This happens in about one pregnancy out of every 100. When it does, about 10% of infants born with congenital HCMV infection can have serious problems after birth with long-lasting problems including hearing loss, mental retardation, seizures and eye problems. Preventing these birth defects will require the development of a safe and effective vaccine against HCMV. Participation in this study will provide background information that is needed to design and study HCMV vaccines in the future. Subjects will receive reimbursement for study visits requiring blood samples.
ELIGIBILITY-We are enrolling 1) healthy infants less than 2 years of age, 2) healthy pregnant women, and 3) healthy adults between the ages of 18 and 50.
SUMMARY- Please see the summary of Antiviral Immune Mechanisms in Early Childhood. The purpose of this study is to understand better how HCMV behaves when it infects healthy adults and how the body's immune system controls the infection. The results of this study will provide important background information that will allow a more accurate assessment of the efficacy of candidate HCMV vaccines as these vaccines enter clinical trials. Subjects will receive reimbursement for their participation.
ELIGIBILITY CRITERIA- We are enrolling 1) Healthy adults between 18 and 50 years of age who are in close contact with infant children less than two and a half years of age and 2) voluntary blood donors who have been recently identified by their physician to have converted to HCMV positive status from a HCMV negative serostatus. A close contact includes parents, home care providers, and day care center workers. . >>>>>
I noticed this one(posted below) about trying to figure out which type of DTaP causes the most reactions as a fifth dose in those kids who had serious reactions with the 4th dose.Really made me mad when I read the part where it says your child needs to have a 5th dose of DTaP to get into school.These kids should NOT be getting any more doses preiod.Oh and that reminds me of the study in teens/adults using a TdcP vaccine(teens and adults spread pertussis so a safe pertussis vaccine is needed for them).
<<
Safety of a Fifth Dose of Diphtheria Tetanus Acellular Pertussis Vaccine (DTaP) in Children Who Had an Extensive Local Reaction After the Fourth DTaP Dose. (Revaccination Study)
SUMMARY: Diphtheria, tetanus, and pertussis are infections that still exist in the world and may cause outbreaks of disease if children are not vaccinated. A vaccine, DTaP, is a childhood immunization, given in a series of 5 injections, that protects children against all three of these infections. Approximately 2% of children have a large area of swelling at the vaccination site after the 4th and/or 5th dose of DTaP. There may also be redness and pain. The reactions go away in a few days. It is not known if a child who had a reaction after dose 4 is more likely to again react to the 5th dose. It is also not known if reactions are more common with some DTaP vaccines than other vaccines. Different DTaP vaccines contain different amounts of vaccine parts. There are currently three DTaP vaccines approved by the FDA for us in the U.S. There are three main purposes of this study: 1) to determine rates and severity of swelling after a 5th dose of DTaP in children who were reported by their parents or health care providers to have had a bad local reaction after dose 4; 2) to compare rates of swelling among two different DTaP vaccines; and 3) to compare antibody levels (proteins that fight germs) in the blood of children who had reactions to those who did not have swelling reactions.
Subjects will have two study visits, the first for a blood sample and to receive their 5th dose of DTaP which is required for entry into school.
The second visit will be solely for a blood sample. This information will help doctors find out why children have these reactions, and also, if one vaccine is more likely to cause this severe swelling reaction. Subjects will receive reimbursement for their participation.
ELIGIBILITY: Children of either sex and any race between the ages of 4 to 6 years will be eligible to enroll as cases if the parent or their medical practitioner were concerned that they had experienced an extensive local reaction after the 4th dose of a DTaP vaccine, and if they have not yet received their 5th DTaP booster dose.
SUMMARY-Human Cytomegalovirus (HCMV) is a common virus that infects most people at some time in their lives. It is not a well-known virus because it does not cause symptoms in most people. The purpose of this study is to understand better how this virus behaves when it infects healthy infants and how the body’s immune system controls the infection. Improved knowledge about HCMV infection in healthy infants is needed because HCMV can cause serious damage to an infant before birth if the mother becomes infected during pregnancy. This happens in about one pregnancy out of every 100. When it does, about 10% of infants born with congenital HCMV infection can have serious problems after birth with long-lasting problems including hearing loss, mental retardation, seizures and eye problems. Preventing these birth defects will require the development of a safe and effective vaccine against HCMV. Participation in this study will provide background information that is needed to design and study HCMV vaccines in the future. Subjects will receive reimbursement for study visits requiring blood samples.
ELIGIBILITY-We are enrolling 1) healthy infants less than 2 years of age, 2) healthy pregnant women, and 3) healthy adults between the ages of 18 and 50.
SUMMARY- Please see the summary of Antiviral Immune Mechanisms in Early Childhood. The purpose of this study is to understand better how HCMV behaves when it infects healthy adults and how the body's immune system controls the infection. The results of this study will provide important background information that will allow a more accurate assessment of the efficacy of candidate HCMV vaccines as these vaccines enter clinical trials. Subjects will receive reimbursement for their participation.
ELIGIBILITY CRITERIA- We are enrolling 1) Healthy adults between 18 and 50 years of age who are in close contact with infant children less than two and a half years of age and 2) voluntary blood donors who have been recently identified by their physician to have converted to HCMV positive status from a HCMV negative serostatus. A close contact includes parents, home care providers, and day care center workers. . >>>>>
